Asset Acquisitions - Schedule of Consideration Paid and Allocation of Costs (Details) - USD ($) $ in Thousands	1 Months Ended
	Aug. 31, 2023	May 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Indemnification Holdback			$ 3,849	$ 4,532
Satiogen
Business Acquisition [Line Items]
Issued common stock		$ 15,585
Cash consideration		2,600
Indemnification Holdback		831
Contingent consideration settled in common stock		4,600
Transaction costs		545
Total purchase consideration		24,161
Assets acquired:
Cash Consideration		2,600
Total assets acquired		24,161
Satiogen | Developed technology
Assets acquired:
Intangible assets		$ 21,561
Bile Acid Medicines
Business Acquisition [Line Items]
Cash consideration	$ 210,378
Transaction costs	2,384
Total purchase consideration	212,762
Assets acquired:
Inventory	12,900
Cash Consideration	210,378
Other current and noncurrent assets	379
Total assets acquired	212,762
Bile Acid Medicines | Developed technology
Assets acquired:
Intangible assets	198,513
Bile Acid Medicines | Assembled workforce
Assets acquired:
Intangible assets	$ 970